Abstract:Abstract From the clinical standpoint, systemic sclerosis (SSc) is characterized by skin and internal organ fibrosis, diffuse fibroproliferative vascular modifications, and autoimmunity. Clinical presentation and course are highly heterogenous and life expectancy variably affected mostly dependent on lung and heart involvement. SSc touches more women than men with differences in disease severity and environmental exposure. Pathogenetic events originate from altered homeostasis favored by genetic predisposition, environmental cues and a variety of endogenous and exogenous triggers. Epigenetic modifications modulate SSc pathogenesis which strikingly associate profound immune-inflammatory dysregulation, abnormal endothelial cell behavior, and cell trans-differentiation into myofibroblasts. SSc myofibroblasts show enhanced survival and enhanced extracellular matrix deposition presenting altered structure and altered physicochemical properties. Additional cell types of likely pathogenic importance are pericytes, platelets, and keratinocytes in conjunction with their relationship with vessel wall cells and fibroblasts. In SSc, the profibrotic milieu is favored by cell signaling initiated in the one hand by transforming growth factor-beta and related cytokines and in the other hand by innate and adaptive type 2 immune responses. Radical oxygen species and invariant receptors sensing danger participate to altered cell behavior. Conventional and SSc-specific T cell subsets modulate both fibroblasts as well as endothelial cell dysfunction. Beside autoantibodies directed against ubiquitous antigens important for enhanced clinical classification, antigen-specific agonistic autoantibodies may have a pathogenic role. Recent studies based on single-cell RNAseq and multi-omics approaches are revealing unforeseen heterogeneity in SSc cell differentiation and functional states. Advances in system biology applied to the wealth of data generated by unbiased screening are allowing to subgroup patients based on distinct pathogenic mechanisms. Deciphering heterogeneity in pathogenic mechanisms will pave the way to highly needed personalized therapeutic approaches.

T-cells and B-cells in systemic sclerosis

Role of B-Cell in the Pathogenesis of Systemic Sclerosis

Current Concepts on the Pathogenesis of Systemic Sclerosis

New insights into CD4(+) T cell abnormalities in systemic sclerosis.

The role of B cells in systemic sclerosis

Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis

Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis

Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis

Immune Cell Dysregulation As a Mediator of Fibrosis in Systemic Sclerosis

Dendritic cells drive profibrotic inflammation and aberrant T cell polarization in systemic sclerosis

Pathophysiology of systemic sclerosis (scleroderma)

Pathogenetic, Clinical and Therapeutic Implications in Systemic Sclerosis

Role of endothelin-1 in the skin fibrosis of systemic sclerosis

Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha

Microchimerism and Systemic Sclerosis

Systemic Sclerosis and Atherosclerosis: Potential Cellular Biomarkers and Mechanisms

Distinct T cell chromatin landscapes in scleroderma subtypes

Pathogenesis of systemic sclerosis-current concept and emerging treatments

TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis

Cytokine‐producing B‐cell balance associates with skin fibrosis in patients with systemic sclerosis

Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis